PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants
- Conditions
- Bioavailability
- Interventions
- Drug: PF-07321332/ritonavir
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05263921
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation
- Conditions
- Bioavailability
- Interventions
- Drug: PF-07321332/ritonavirDrug: PF-07321332
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05263895
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 160
- Registration Number
- NCT05261139
- Locations
- 🇺🇸
University of Alabama at Birmingham - School of Medicine, Birmingham, Alabama, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
- Conditions
- Breast CancerSolid Tumors
- Interventions
- Drug: PF-07220060 + PF-07104091 combination dose escalationDrug: PF-07104091 + PF-07220060 + fulvestrant dose expansionDrug: PF-07104091 + PF-07220060 + letrozole dose expansion
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 240
- Registration Number
- NCT05262400
- Locations
- 🇺🇸
Administrative Address: UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸UCLA Hematology/Oncology, Los Angeles, California, United States
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
- Conditions
- Fallopian Tube CancerOvarian CancerOvarian NeoplasmsOvarian CarcinomaEpithelial Ovarian CancerPrimary Peritoneal Carcinoma
- Interventions
- Drug: maplirpacept (PF-07901801)Drug: Pegylated Liposomal Doxorubicin (PLD)
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT05261490
- Locations
- 🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
🇺🇸oncology Consultants, P.A., Houston, Texas, United States
🇺🇸Oklahoma Cancer Specialist and Research Institute. LLC, Tulsa, Oklahoma, United States
Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders
- Conditions
- Temporomandibular Disorders (TMD)
- Interventions
- Drug: PlaceboDrug: Rimegepant
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 126
- Registration Number
- NCT05262517
- Locations
- 🇺🇸
The Medici Medical Research, LLC, Hollywood, Florida, United States
🇺🇸The Medici Medical Research, Hollywood, Florida, United States
🇺🇸Clinvest Research, LLC, Springfield, Missouri, United States
Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05260684
- Locations
- 🇺🇸
Pfizer Investigational Site, New York, New York, United States
PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
- Conditions
- Bladder Cancer
- Interventions
- Drug: PF-07225570Drug: sasanlimab
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05259397
- Locations
- 🇵🇱
Szpital Specjalistyczny im. Sw. Rodziny SPZOZ, Warszawa, Poland
🇵🇱Medical Concierge Centrum Medyczne, Warszawa, Poland
🇺🇸Columbia University Medical Center - Herbert Irving Pavilion, New York, New York, United States
A Study to Learn About The Study Medicine (Called PF-06823859) in Healthy Chinese Participants
- Conditions
- Healthy
- Interventions
- Other: PlaceboDrug: IFN-β inhibitor treatment
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT05257798
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 112
- Registration Number
- NCT05250115
- Locations
- 🇩🇪
Elbe Kliniken Stade - Buxtehude GmbH, Buxtehude, Niedersachsen, Germany
🇩🇪ÜUeberoertliche Gemeinschaftspraxis Jost Kai Rietkoetter Robert Jablonka, Gelsenkirchen, Nordrhein-westfalen, Germany
🇩🇪Dermatologische Gemeinschaftspraxis Dres. Quist PartG, Mainz, Rheinland-pfalz, Germany